Fate Therapeutics Inc. (FATE)
| Bid | 1.23 |
| Market Cap | 141.54M |
| Revenue (ttm) | 13.63M |
| Net Income (ttm) | -186.26M |
| EPS (ttm) | -1.64 |
| PE Ratio (ttm) | -0.75 |
| Forward PE | -0.97 |
| Analyst | Hold |
| Ask | 1.24 |
| Volume | 656,585 |
| Avg. Volume (20D) | 2,363,781 |
| Open | 1.28 |
| Previous Close | 1.28 |
| Day's Range | 1.23 - 1.31 |
| 52-Week Range | 0.66 - 5.92 |
| Beta | 2.42 |
About FATE
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat mul...
Analyst Forecast
According to 8 analyst ratings, the average rating for FATE stock is "Hold." The 12-month stock price forecast is $5, which is an increase of 304.86% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · seekingalpha.com
Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking CheapFate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies that could help oncology and immunology patients. Their pipeline has 3 interesting Phase 1 candidates for SLE, So...